WuXi PharmaTech (NYSE: WX) reported earnings on May 10. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), WuXi PharmaTech beat expectations on revenues and earnings per share.

Compared with the prior-year quarter, revenue increased significantly and GAAP earnings per share increased significantly.

Margins dropped across the board.

Revenue details
WuXi PharmaTech logged revenue of $118.0 million. The eight analysts polled by S&P Capital IQ anticipated a top line of $114.1 million on the same basis. GAAP reported sales were 26% higher than the prior-year quarter's $93.6 million.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.33. The seven earnings estimates compiled by S&P Capital IQ anticipated $0.26 per share. GAAP EPS of $0.28 for Q1 were 17% higher than the prior-year quarter's $0.24 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 35.5%, 160 basis points worse than the prior-year quarter. Operating margin was 17.5%, 370 basis points worse than the prior-year quarter. Net margin was 17.8%, 170 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $118.6 million. On the bottom line, the average EPS estimate is $0.32.

Next year's average estimate for revenue is $476.0 million. The average EPS estimate is $1.21.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 331 members out of 353 rating the stock outperform, and 22 members rating it underperform. Among 73 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 69 give WuXi PharmaTech a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on WuXi PharmaTech is outperform, with an average price target of $17.68.

Over the decades, small-cap stocks like WuXi PharmaTech have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Get instant access to this free report.